STAT+: Pharmalittle: We’re reading about a Huntington’s gene therapy, Novo’s challenges, and more

STAT+: Pharmalittle: We’re reading about a Huntington’s gene therapy, Novo’s challenges, and more →

UniQure has submitted its Huntington’s gene therapy to the FDA, investors remain unenthusiastic on Novo Nordisk, and more of the latest pharma headlines in today's Pharmalittle newsletter.